Finance

Beta
Lists
NAMS:NASDAQ
NewAmsterdam Pharma Company NV
US$ ३२.६३
+३.९२%
(+१.२३) 1D
US$ ३२.६३
०.००% (०.००)
After hours
Closed: जुन २४, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NAMS...
Open
US$ ३१.५५
High
US$ ३३.०४
Low
US$ ३१.५०
Mkt. cap
३.८२ अरब
Avg. vol.
१३.९९ लाख
Volume
१२.३६ लाख
52-wk high
US$ ४२.२०
52-wk low
US$ १७.६७
EPS
-US$ १.७७
Beta
०.०८
Shares outstanding
११.६९ करोड
No. of employees
१००
Open
US$ ३१.५५
High
US$ ३३.०४
Low
US$ ३१.५०
Mkt. cap
३.८२ अरब
Avg. vol.
१३.९९ लाख
Volume
१२.३६ लाख
52-wk high
US$ ४२.२०
52-wk low
US$ १७.६७
EPS
-US$ १.७७
Beta
०.०८
Shares outstanding
११.६९ करोड
No. of employees
१००
News stories
From sources across the web
Stock Titan
Stock Titan
·
२ घण्टा पहिले
NewAmsterdam Pharma (NAMS) CAO exercises options and sells 40,000 shares
About NewAmsterdam Pharma Company NV
CEO-
Employees१००
Founded२०१९
Headquarters-
Sector-
Websitenewamsterdampharma.com
Analyst Ratings
Based on 10 analysts giving stock ratings to NAMS in the past 3 months
Strong Buy
Buy
9
Hold
1
Sell
0
12 month forecast
Based on 10 Wall Street analysts offering 12 month price targets for NAMS in the last 3 months.
Highest
Current US$ ३२.६३
US$ ६०.०० (+८३.८८%)
Average
US$ ४७.८६ (+४६.६७%)
Lowest
US$ ३८.०० (+१६.४६%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
US$ ६०.००
+८३.९%
05/12/2026
Srikripa Devarakonda
Truist Financial
Buy
Maintained
-
-
05/08/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
US$ ४५.००
+३७.९%
05/07/2026
Serge Belanger
Needham
Buy
Maintained
US$ ४८.००
+४७.१%
05/07/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/07/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
05/07/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
US$ ५२.००
+५९.४%
05/06/2026
Asad Haider
Goldman Sachs
Hold
Maintained
US$ ३८.००
+१६.५%
05/07/2026
Leonid Timashev
RBC Capital
Buy
Maintained
US$ ४७.००
+४४%
05/06/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
US$ ४५.००
+३७.९%
04/02/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
US$ ४५.००
+३७.९%
04/02/2026
Steven Seedhouse
Cantor Fitzgerald
Buy
Reiterated
US$ ४९.००
+५०.२%
02/19/2026
James Condulis
Stifel Nicolaus
Buy
Maintained
US$ ५०.००
+५३.२%
02/06/2026
Geoff Meacham
Citi
Buy
Maintained
US$ ५५.००
+६८.६%
01/30/2026
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
Revenue
१.९१ करोड
३.४८ लाख
३२.०० हजार
३०.४० लाख
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
२.७५ करोड
३.१० करोड
३.८६ करोड
३.८० करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
२.७३ करोड
२.४५ करोड
२.७४ करोड
२.३५ करोड
Operating expense
५.४८ करोड
५.५५ करोड
६.६० करोड
६.१५ करोड
Total operating expenses
५.४८ करोड
५.५५ करोड
६.६० करोड
६.१५ करोड
Operating income
-३.५६ करोड
-५.५१ करोड
-६.६० करोड
-५.८४ करोड
Other non operating income
२५.९० लाख
-२.३८ करोड
-१.५३ करोड
५९.४२ लाख
EBT including unusual items
-१.७४ करोड
-७.२० करोड
-७.४९ करोड
-४.८४ करोड
EBT excluding unusual items
-१.७४ करोड
-७.२० करोड
-७.४९ करोड
-४.८४ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-१.७४ करोड
-७.२० करोड
-७.४९ करोड
-४.८४ करोड
Net profit margin
-९०.७०%
-२०,६९१.०९%
-२,३४,१३४.३८%
-१,५९३.४५%
Earnings per share
-
-
-
-
Interest and investment income
७०.५५ लाख
६७.१३ लाख
६४.७३ लाख
५६.५० लाख
Interest expense
-
-
-
-
Net interest expenses
७०.५५ लाख
६७.१३ लाख
६४.७३ लाख
५६.५० लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-३.५६ करोड
-५.५१ करोड
-६.५९ करोड
-५.८४ करोड
Gain or loss from assets sale
-
१.०० हजार
११.०० हजार
१२.०० हजार
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer